First-line Gemcitabine

Adult Aged Breast Neoplasms / drug therapy Deoxycytidine / adverse effects Female Humans Middle Aged Neoplasm Metastasis Physicians Prospective Studies Quality of Life Treatment Failure Gemcitabine
Metastatic breast cancer gemcitabine treatment of physician’s choice

Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 16 01 2021
revised: 26 01 2021
accepted: 27 01 2021
entrez: 31 3 2021
pubmed: 1 4 2021
medline: 10 4 2021
Statut: ppublish

Résumé

This study aimed to investigate the efficacy of first-line gemcitabine monotherapy for metastatic breast cancer (MBC) and its effect on health-related quality of life (HRQoL) compared with treatment of physician's choice (TPC). We enrolled 96 patients into the first-line gemcitabine group (n=47) or other treatment of physician's choice (TPC) group (n=49) from May 2010 to April 2013. HRQoL was evaluated every 4 weeks. There was no significant difference in the median time to treatment failure (5.3 vs. 4.6 months, hazard ratio=0.87, p=0.546) and the incidence rates of grade 3/4 haematological toxicity (10.6% vs. 8.1%, p=0.677) and grade 3/4 non-haematological toxicity (4.2% vs. 8.1%, p=0.429) between the gemcitabine and TPC groups. Changes in HRQoL from baseline to 12 weeks were not significantly different. Gemcitabine achieves similar efficacy and HRQoL benefit to other chemotherapy and can be used as first-line treatment for MBC.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
This study aimed to investigate the efficacy of first-line gemcitabine monotherapy for metastatic breast cancer (MBC) and its effect on health-related quality of life (HRQoL) compared with treatment of physician's choice (TPC).
PATIENTS AND METHODS METHODS
We enrolled 96 patients into the first-line gemcitabine group (n=47) or other treatment of physician's choice (TPC) group (n=49) from May 2010 to April 2013. HRQoL was evaluated every 4 weeks.
RESULTS RESULTS
There was no significant difference in the median time to treatment failure (5.3 vs. 4.6 months, hazard ratio=0.87, p=0.546) and the incidence rates of grade 3/4 haematological toxicity (10.6% vs. 8.1%, p=0.677) and grade 3/4 non-haematological toxicity (4.2% vs. 8.1%, p=0.429) between the gemcitabine and TPC groups. Changes in HRQoL from baseline to 12 weeks were not significantly different.
CONCLUSION CONCLUSIONS
Gemcitabine achieves similar efficacy and HRQoL benefit to other chemotherapy and can be used as first-line treatment for MBC.

Identifiants

DOI: 10.21873/anticanres.14930 PMID: 33788764
pubmed: 33788764
pii: 41/3/1671
doi: 10.21873/anticanres.14930
doi:

Substances chimiques

Deoxycytidine 0W860991D6
Gemcitabine 0

Types de publication

Comparative Study Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1671-1676

Informations de copyright

Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Shinya Yamamoto (S)

Yokohama City University Medical Center, Department of Breast and Thyroid Surgery, Yokohama, Japan.

Kazutaka Narui (K)

Yokohama City University Medical Center, Department of Breast and Thyroid Surgery, Yokohama, Japan; nr1@gc5.so-net.ne.jp.

Takashi Ishikawa (T)

Yokohama City University Medical Center, Department of Breast and Thyroid Surgery, Yokohama, Japan.

Shoko Adachi (S)

Yokohama City University Medical Center, Department of Breast and Thyroid Surgery, Yokohama, Japan.

Kazuhiro Shimada (K)

Yokohama City University Medical Center, Department of Breast and Thyroid Surgery, Yokohama, Japan.

Daisuke Shimizu (D)

Yokohama City University Medical Center, Department of Breast and Thyroid Surgery, Yokohama, Japan.

Akimitsu Yamada (A)

Yokohama City University Graduate School of Medicine, Department of Gastroenterological Surgery, Yokohama, Japan.

Sadatoshi Sugae (S)

Yokohama City University Graduate School of Medicine, Department of Gastroenterological Surgery, Yokohama, Japan.

Mikiko Tanabe (M)

Yokohama City University Medical Center, Department of Pathology, Yokohama, Japan.

Mari Oba (M)

Yokohama City University Medical Center, Department of Biostatics and Epidemiology, Yokohama, Japan.

Satoshi Morita (S)

Kyoto University Graduate School of Medicine, Department of Biomedical Statistics and Bioinformatics, Kyoto, Japan.

Takako Doi (T)

Shonan Kinen Hospital, Breast Center, Kamakura, Japan.

Satoshi Hasegawa (S)

Saiseikai Yokohama-shi Nanbu Hospital, Department of Surgery, Yokohama, Japan.

Tomoyuki Morita (T)

Yokosuka Kyosai Hospital, Department of Surgery, Yokosuka, Japan.

Ayako Kito (A)

Yokohama Municipal Citizen's Hospital, Department of Breast Surgery, Yokohama, Japan.

Takashi Chishima (T)

Yokohama Rosai Hospital, Department of Breast Surgery, Yokohama, Japan.

Yasushi Ichikawa (Y)

Yokohama City University Graduate School of Medicine, Department of Clinical Oncology, Yokohama, Japan.

Itaru Endo (I)

Yokohama City University Graduate School of Medicine, Department of Gastroenterological Surgery, Yokohama, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › First-line Gemcitabine
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › First-line Gemcitabine
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › First-line Gemcitabine
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléosides › Nucléosides pyrimidiques › Désoxycytidine › First-line Gemcitabine
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › First-line Gemcitabine
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › First-line Gemcitabine
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Métastase tumorale › First-line Gemcitabine
questionsmedicales.fr › Établissements, main d'oeuvre et services de soins de santé › Personnel de santé › Médecins › First-line Gemcitabine
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › First-line Gemcitabine
questionsmedicales.fr › Environnement et santé publique › Santé publique › Mesures épidémiologiques › Démographie › État de santé › Qualité de vie › First-line Gemcitabine
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Échec thérapeutique › First-line Gemcitabine
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines › Gemcitabine › First-line Gemcitabine